We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A late-stage trial of Eli Lilly’s rheumatoid arthritis (RA) treatment Olumiant (baricitinib) and Gilead Sciences’ remdesivir found that the combination reduced recovery time in hospitalized COVID-19 patients compared to remdesivir alone. Read More
The UK government has signed a $1.5 billion agreement with Valneva to supply up to 190 million doses of the French company’s COVID-19 vaccine — enough to provide multiple doses to the UK’s population of almost 68 million. Read More
The pharma industry is pledging to take President Trump’s new executive order aimed at lowering drug prices to court even as Trump considers implementing the order ahead of the Nov. 3 presidential election. Read More
Although the FDA has been especially vigilant towards websites selling sham COVID-19 products during the pandemic, it’s still keeping an eye out for unlawful opioid vendors, and it issued multiple warning letters last week to online firms that illegally sold opioid products. Read More
Roche has unveiled new data for its multiple sclerosis drug Ocrevus (ocrelizumab) that further supports its ability to hinder disease progression. The positive new findings come shortly after the FDA’s recent approval of Novartis’ Kesimpta (ofatumumab), a drug that could prove to be a formidable rival to Roche’s blockbuster product. Read More
AstraZeneca announced on Saturday that it has resumed its phase 3 COVID-19 vaccine trial in the UK after pausing it last Tuesday due to a single “unexplained illness.” Read More
Refocusing new drug R&D to a more patient-centric approach, an using new technology alongside soft skills like empathy and collaboration, are among the changes the pharmaceutical industry can expect in coming years. Read More
The abuse-deterrent formulation of Purdue Pharma’s OxyContin (oxycodone Hcl) does have some benefit in reducing abuse of the opioid medication, a joint meeting of two FDA advisory committees decided in three separate votes on Friday. Read More